ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2020
COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 2 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Cardiopulmonary crosstalk in Long COVID: a systematic review of emerging evidence.BMC cardiovascular disorders · 2025Pooled it
- New-Onset Diabetes Mellitus, Hypertension, Dyslipidaemia as Sequelae of COVID-19 Infection-Systematic Review.International journal of environmental research and public health · 2022Pooled it
- A quantitative metabolic signature of host response during SARS-CoV-2 infection and recovery.iScience · 2026Article
- Assessment of biochemical and hematological profiles in outpatients with serological evidence of SARS-CoV-2 infection.Frontiers in medicine · 2026Article
- The Metabolic Aftershock: COVID-19 and Metabolic Disease Risk Among U.S. Active-Duty Military Personnel.Metabolites · 2025Article
- The relationship between the triglyceride to high-density lipoprotein cholesterol ratio and positive blood or pus cultures in patients with pyogenic liver abscess.Lipids in health and disease · 2025Article
- Carbon dots: A promising tool for viral infection treatment.Materials today. Bio · 2025Review
- Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients.Scientific reports · 2025Article
- HDL proteome and apolipoproteins concentrations in severe ICU COVID-19 patients.Lipids in health and disease · 2025Article
- Bridging the gap between CVD and COVID-19: the oxidized LDL hypothesis.Frontiers in medicine · 2025Article
- A six-year study in a real-world population reveals an increased incidence of dyslipidemia during COVID-19.The Journal of clinical investigation · 2024Article
- Targeting host-specific metabolic pathways-opportunities and challenges for anti-infective therapy.Frontiers in molecular biosciences · 2024Review
- Evolution of Cardiovascular Risk Factors in Post-COVID Patients.Journal of clinical medicine · 2023Article
- Metabolomics-directed nanotechnology in viral diseases management: COVID-19 a case study.Pharmacological reports : PR · 2023Review
- COVID Vaccination as a Strategy for Cardiovascular Disease Prevention.Current cardiology reports · 2023Review
- Multi-Omic Candidate Screening for Markers of Severe Clinical Courses of COVID-19.Journal of clinical medicine · 2023Article
- Low HDL-c levels at admission are associated with greater severity and worse clinical outcomes in patients with COVID-19 disease.Atherosclerosis plus · 2023Article
- SARS-CoV-2 induced HDL dysfunction may affect the host's response to and recovery from COVID-19.Immunity, inflammation and disease · 2023Review
- Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study.Scientific reports · 2023Article
- Phenotypic changes in low-density lipoprotein particles as markers of adverse clinical outcomes in COVID-19.Molecular genetics and metabolism · 2023Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The current coronavirus disease 2019 (COVID-19) pandemic presents a global challenge for managing acutely ill patients and complications from viral infection. Systemic inflammation accompanied by a "cytokine storm," hemostasis alterations and severe vasculitis have all been reported to occur with COVID-19, and emerging evidence suggests that dysregulation of lipid transport may contribute to some of these complications. Here, we aim to summarize the current understanding of the potential mechanisms related to COVID-19 dyslipidemia and propose possible adjunctive type therapeutic approaches that modulate lipids and lipoproteins. Specifically, we hypothesize that changes in the quantity and composition of high-density lipoprotein (HDL) that occurs with COVID-19 can significantly decrease the anti-inflammatory and anti-oxidative functions of HDL and could contribute to pulmonary inflammation. Furthermore, we propose that lipoproteins with oxidized phospholipids and fatty acids could lead to virus-associated organ damage via overactivation of innate immune scavenger receptors. Restoring lipoprotein function with ApoA-I raising agents or blocking relevant scavenger receptors with neutralizing antibodies could, therefore, be of value in the treatment of COVID-19. Finally, we discuss the role of omega-3 fatty acids transported by lipoproteins in generating specialized proresolving mediators and how together with anti-inflammatory drugs, they could decrease inflammation and thrombotic complications associated with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.